Abstract
Hib conjugate vaccine was developed with the ultimate goal of providing an effective vaccine for infants and younger children. The conjugate vaccine is as safe as Hib polysaccharide vaccine and significantly more immunogenic. Because antibody production after vaccination with conjugate vaccine in children 18 months of age or older is substantially greater than after vaccination with polysaccharide vaccine, conjugate vaccine has been licensed for use in these children. Pediatric nurse practitioners should educate parents about the importance of the new Hib conjugate vaccine in prevention of Hib disease in children 18 months and older. The safety and efficacy of the new vaccine in children less than 18 months of age are currently under study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
